Patents by Inventor Tanweer Khan

Tanweer Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250026731
    Abstract: The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.
    Type: Application
    Filed: June 14, 2024
    Publication date: January 23, 2025
    Inventors: Srinivas RAO, Glenn SHORT, Robert B. PERNI, Tanweer A. KHAN, Alan C. GIBBS
  • Publication number: 20240425470
    Abstract: Provided herein are compounds of Formula (I) and Formula (II), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and (II) or a pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) and (II) or a pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental disease or disorder.
    Type: Application
    Filed: June 7, 2024
    Publication date: December 26, 2024
    Inventors: Tanweer A. KHAN, Glenn SHORT, Robert B. PERNI
  • Publication number: 20240400511
    Abstract: Provided herein are compounds of Formula (I), (II), or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (II), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 7, 2024
    Publication date: December 5, 2024
    Inventors: Robert B. PERNI, Glenn SHORT, Tanweer A. KHAN
  • Publication number: 20240400532
    Abstract: Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (II), e.g., in the treatment of a mental health disease or disorder.
    Type: Application
    Filed: January 29, 2024
    Publication date: December 5, 2024
    Inventors: Robert B. Perni, Glenn Short, Tanweer A. Khan
  • Publication number: 20240376116
    Abstract: Provided herein are compounds of Formula (I), (II), (III), or pharmaceutically acceptable salt, prodrug, or steroisomer thereof, and compositions thereof, wherein R1, R1?, R2, R2?, R3, R6, R7, X1, X2, X3, X4, and Z are defined herein. The disclosed compounds are useful for treating various conditions, including alcoholism, substance abuse disorder, and opioid use disorder.
    Type: Application
    Filed: April 25, 2024
    Publication date: November 14, 2024
    Inventors: Tanweer A. KHAN, Glenn SHORT, Robert B. PERNI, Alan C. GIBBS, Jeffrey O'MEARA, Harpreet KAUR, Ahmed Magdy ALI
  • Publication number: 20240366542
    Abstract: Methods of treating a stress-related disease or disorder such as PTSD and mood/depressive disorder, inducing neurite outgrowth, or inducing structural neuroplasticity, comprising administering to a subject a composition comprising an effective amount of a compound that does not have an agonist activity on 5-HT2A serotonin receptor are disclosed. Also disclosed are pharmaceutical compositions comprising compound not having an agonist activity on 5-HT2A serotonin receptor and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 7, 2023
    Publication date: November 7, 2024
    Inventors: Tanweer A. Khan, Alan C. Gibbs, Glenn F. Short, Robert B. Perni
  • Publication number: 20240300885
    Abstract: Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
    Type: Application
    Filed: August 23, 2023
    Publication date: September 12, 2024
    Applicant: ATAI Life Sciences AG
    Inventors: Glenn SHORT, Robert B. PERNI, Tanweer A. KHAN
  • Publication number: 20240294461
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
    Type: Application
    Filed: February 7, 2024
    Publication date: September 5, 2024
    Inventors: Glenn Short, Robert B. Perni, Benjamin Robert Difrancesco, Tanweer A. Khan
  • Publication number: 20240287107
    Abstract: Provided herein are compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B), pharmaceutically acceptable salts thereof, and compositions thereof, wherein R1, R2, R3, R7, R8, R9, R10, R11, R12, R13, R14, A, B, E, W, X, and n are defined herein. The disclosed compounds are useful for treating various diseases, including depression and associated conditions.
    Type: Application
    Filed: May 1, 2024
    Publication date: August 29, 2024
    Inventors: Tanweer A. KHAN, Robert B. PERNI, Alan C. GIBBS
  • Patent number: 12065405
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 12, 2023
    Date of Patent: August 20, 2024
    Assignee: ATAI Therapeutics, Inc.
    Inventors: Robert B. Perni, Glenn Short, Srinivas G. Rao, Tanweer A. Khan
  • Patent number: 12012381
    Abstract: Provided herein are compounds of Formula (I), (II), or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (II), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: June 18, 2024
    Assignee: ATAI THERAPEUTICS, INC.
    Inventors: Robert B. Perni, Glenn Short, Tanweer A. Khan
  • Patent number: 11976268
    Abstract: The present invention relates generally to growth of bacteria. More specifically the invention relates to a method for oxidative environment adaptation of anaerobic microorganisms and their use in developing new probiotics. In particular, the present invention provides a method for adaptation of anaerobic microorganisms and selection of more oxygen tolerant anaerobic microorganisms, said method comprising the steps of culturing said microorganisms with a stepwise dual induction of oxidative stress via applied voltage and oxygen diffusion, and a stepwise change of anti-oxidant/oxidized counterpart concentration ratio to adjust the redox state. New strains are also provided.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: May 7, 2024
    Assignee: BIOGAIA AB
    Inventors: Muhammad-Tanweer Khan, Fredrik Backhed
  • Publication number: 20240116896
    Abstract: The present disclosure provides N,N-dimethyltryptamine (N,N-DMT) derivatives of the present disclosure provides compounds of formula (I), (I-A), (I-B), (I-C), (II), (II-A), (III), and (IV), or pharmaceutically acceptable salts or deuterated forms thereof. Also provided herein are methods of using the N,N-DMT derivatives, e.g., in the treatment of mental health diseases and/or disorders.
    Type: Application
    Filed: September 6, 2023
    Publication date: April 11, 2024
    Inventors: Tanweer A. KHAN, Alan C. GIBBS, Glenn SHORT, Robert B. PERNI
  • Patent number: 11926574
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: March 12, 2024
    Assignee: Atai Therapeutics Inc.
    Inventors: Glenn Short, Robert B. Perni, Benjamin Robert Difrancesco, Tanweer A. Khan
  • Patent number: 11912680
    Abstract: Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (III), e.g., in the treatment of a mental health disease or disorder.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: February 27, 2024
    Assignee: EmpathBio, Inc.
    Inventors: Robert B. Perni, Glenn Short, Tanweer A. Khan
  • Patent number: 11845736
    Abstract: The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: December 19, 2023
    Assignee: EmpathBio, Inc.
    Inventors: Srinivas Rao, Glenn Short, Robert B. Perni, Tanweer A. Khan, Alan C. Gibbs
  • Patent number: 11827580
    Abstract: Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (M-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
    Type: Grant
    Filed: December 27, 2022
    Date of Patent: November 28, 2023
    Assignee: ATAI Life Sciences AG
    Inventors: Glenn Short, Robert B. Perni, Tanweer A. Khan
  • Publication number: 20230357146
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: April 12, 2023
    Publication date: November 9, 2023
    Inventors: Robert B. PERNI, Glenn SHORT, Srinivas G. RAO, Tanweer A. KHAN
  • Patent number: 11766435
    Abstract: The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: September 26, 2023
    Assignees: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research
    Inventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
  • Publication number: 20230227420
    Abstract: The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.
    Type: Application
    Filed: October 3, 2022
    Publication date: July 20, 2023
    Inventors: Srinivas RAO, Glenn SHORT, Robert B. PERNI, Tanweer A. KHAN, Alan C. GIBBS